Treatment of Cardiac Amyloidosis in Amyloid Light Chain (AL) Amyloidosis

Clinical Scenario

This protocol addresses cardiac amyloidosis arising in the context of amyloid light chain (AL) amyloidosis — a subtype driven by an underlying haematological disorder producing abnormal immunoglobulin light chains that deposit in cardiac tissue.

Why This Subtype Matters

Amyloid light chain cardiac amyloidosis is associated with more rapid progression of heart failure and worse prognosis than ATTR. Identifying this specific subtype shapes the treatment strategy significantly.

Treatment Approach (Partial)

Management targets the underlying haematological source. The approach involves systemic therapy directed at the plasma cell clone — the full protocol specifies the regimen options and sequencing.

Instant Access to Structured Evidence-Based Regimens

References

Amyloid light chain cardiac amyloidosis is associated with more rapid progression of heart failure and worse prognosis than ATTR.
Therapy for AL cardiac amyloidosis is based on treatment of the underlying haematological problem with chemotherapy or autologous stem-cell transplant.

DOI: 10.1093/eurheartj/ehad194

View source ↗